Hartnett, P; Buck, M; Beale, Phillip; Goldrick, A; Allan, S; Fitzharris, B; de Souza, P; Links, M; Kalimi, G; Davies, T; Stuart-Harris, Robin
Gemcitabine and oxaliplatin have shown single-agent activity in relapsed ovarian cancer. This combination was used to determine response rates, time-to-event efficacy measures, and toxicity in patients with recurrent ovarian cancer. Patients with prior platinum-based chemotherapy who had measurable lesions and/or elevated CA-125 levels were identified as group A (platinum-refractory/platinum-resistant patients) and group B (platinum-sensitive patients). All patients received gemcitabine 1000...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.